(R)-2-(4-Chloro-N-(2-Fluoro-4-(N'-Hydroxycarbamimidoyl)Benzyl)Phenylsulfonamido)-5,5,5-Trifluoropentanamide 以 甲醇,水,乙腈 用作溶剂,化学反应 4.0H,反应生成γ-Secretase抑制剂(Bms-708163) 参考文献:Novel Alpha-(N-Sulfonamido)Acetamide Compound As An Inhibitor Of Beta Amyloid Peptide Production 标题:Novel Alpha-(N-Sulfonamido)Acetamide Compound As An Inhibitor Of Beta Amyloid Peptide Production 摘要:本发明提供了一种新型的α-(N-磺胺基)乙酰胺化合物,其药物组合物,其制备方法以及用于治疗阿尔茨海默病和其他与β-淀粉样肽相关疾病的方法.
专利号:US-10682335-B2 优先权日:2014-07-28 标题 :Use of butylidenephthalide (Bdph), method of using the same, and method for preparing pharmaceutical composition containing the same 发明人:SU HONG-LIN; CHANG CHIA-YU; HWANG SHIAW-MIN; Lu huai-en; HARN HORNG-JYH; LIN SHINN-ZONG; LAI PING-SHAN 权利人:EVERFRONT BIOTECH INC 摘要:The present invention discloses use of butylidenephthalide (Bdph), a method of using the same, and a method for preparing a pharmaceutical composition containing the same. Because Bdph has the capability of promoting the hair growth and reducing the β-amyloid protein (Aβ) level in nerve cells, the efficacy of improving the health and appearance of a subject can be achieved by administrating an effective amount of Bdph to the subject. Specifically, the Bdph has the efficacy of preventing or treating neurodegenerative diseases such as Alzheimer's disease caused by excessive build up of Aβ in the cells, and as an active ingredient in a topical composition, the Bdph is effective in promoting the hair growth at the site where the Bdph is administered. Furthermore, the method for preparing a pharmaceutical composition containing Bdph comprises preparing the pharmaceutical composition through an organic synthesis reaction, wherein the Bdph is coated with a polymeric material such as F127 by covalent bonding of the polymeric material with the Bdph, thereby achieving the effect of reducing the cytotoxicity of the pharmaceutical composition for an organism.
专利号:US-9771379-B2 优先权日:2015-09-24 标题:N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]OXAZIN-8a(8H)-yl)-thiazol-4-yl) amides 发明人:BRODNEY MICHAEL AARON; BUTLER CHRISTOPHER RYAN; ZHANG LEI; O'NEILL BRIAN THOMAS 权利人:PFIZER 摘要:The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, n nwherein the variables R 1 , R 2 , R 3 , R 4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
专利号:US-8962616-B2 优先权日:2012-05-04 标 题:Heterocyclic substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds 发明人:BRODNEY MICHAEL AARON; BUTLER CHRISTOPHER RYAN; BECK ELIZABETH MARY; DAVOREN JENNIFER ELIZABETH; O'NEILL BRIAN THOMAS 权利人:PFIZER 摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
专利号:US-9744173-B2 优先权日:2014-04-10 标题 :2-amino 6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides 发明人:BRODNEY MICHAEL AARON; BECK ELIZABETH MARY; BUTLER CHRISTOPHER RYAN; ZHANG LEI; O'NEILL BRIAN THOMAS; BARREIRO GABRIELA; LACHAPELLE ERIK ALPHIE; ROGERS BRUCE NELSEN 权利人:PFIZER 摘要:The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, n nand the variable R 1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
专利号:US-9751895-B2 优先权日:2015-09-24 标 题:N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl)-1,3-thiazol-4-yl]amides 发明人:BRODNEY MICHAEL AARON; BUTLER CHRISTOPHER RYAN; ZHANG LEI; O'NEILL BRIAN THOMAS; VERHOEST PATRICK ROBERT; MIKOCHIK PETER JUSTIN; MURRAY JOHN CHARLES; HOU XINJUN 权利人:PFIZER 摘要:The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, n nand the variables R 1 , R 2 and R 3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
专利号:US-9260455-B2 优先权日:2012-09-20 标 题 :Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds 发明人:BRODNEY MICHAEL AARON; BECK ELIZABETH MARY; BUTLER CHRISTOPHER RYAN; DAVOREN JENNIFER ELIZABETH 权利人:PFIZER 摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, n nwherein the variables R 1 and R 2 are as defined in the specification.n n Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
1: Yang G, Zhou R, Guo X, Yan C, Lei J, Shi Y. Structural basis of γ-secretase inhibition and modulation by small molecule drugs. Cell. 2021 Jan 21;184(2):521-533.e14. doi: 10.1016/j.cell.2020.11.049. Epub 2020 Dec 28. 163(2):525-542. doi: 10.1093/toxsci/kfy048. 72(11):1324-33. doi: 10.1001/jamaneurol.2015.0607. 344(3):686-95. doi: 10.1124/jpet.112.199356. Epub 2012 Dec 28. 32(11):761-9. doi: 10.1007/s40261-012-0006-4. 91(12):1316-1324. doi: 10.1136/jnnp-2020-323497. Epub 2020 Oct 12. 69(11):1430-40. doi: 10.1001/archneurol.2012.2194. 75(1):136-45. doi: 10.1111/j.1365-2125.2012.04339.x. 9: Sivaraman L, Sanderson T. Gamma secretase inhibition: Effects on fertility and embryo-fetal development in rats. Toxicol Appl Pharmacol. 2023 Jun 15;469:116512. doi: 10.1016/j.taap.2023.116512. Epub 2023 Apr 6. 51(10):681-93. doi: 10.1007/s40262-012-0005-x. 34(3):654-67. doi: 10.1016/j.clinthera.2012.01.022. Epub 2012 Feb 28. 55(6):5047-5058. doi: 10.1007/s12035-017-0705-1. Epub 2017 Aug 16. 13: Simutis FJ, Sanderson TP, Pilcher GD, Graziano MJ. Investigations on the Relationship Between Ovarian, Endocrine, and Renal Findings in Nonclinical Safety Studies of the γ-Secretase Inhibitor Avagacestat. Toxicol Sci. 2019 Sep 1;171(1):98-116. doi: 10.1093/toxsci/kfz129. 57(10):600-5. doi: 10.1002/jlcr.3224. Epub 2014 Sep 5. 13(4):514. doi: 10.3390/pharmaceutics13040514.
合成参考文献
参考文献:10.1124/jpet.112.199356 摘要:Albright CF, Dockens RC, Meredith JE, Olson RE, Slemmon R, Lentz KA, Wang J, Denton RR, Pilcher G, Rhyne PW, Raybon JJ, Barten DM, Burton C, Toyn JH, Sankaranarayanan S, Polson C, Guss V, White R, Simutis F, Sanderson T, Gillman KW, Starrett JE, Bronson J, Sverdlov O, Huang S, Castaneda L, Feldman H, Coric V, Zaczek R, Macor JE, Houston J, Berman RM, Tong G. Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat. The Journal of Pharmacology and Experimental Therapeutics. 2013 Mar;344(3):686–95. doi: 10.1124/jpet.112.199356. 参考文献:10.1007/s00228-012-1459-3 摘要:Niva C, Parkinson J, Olsson F, van Schaick E, Lundkvist J, Visser SAG. Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD A model-based meta-analysis of γ-secretase inhibitor data. European Journal of Clinical Pharmacology. 2013 Jan 04;69(6):1247–60. doi: 10.1007/s00228-012-1459-3. 参考文献:10.1007/s12035-019-01677-8 摘要:Lopez-Font I, Boix CP, Zetterberg H, Blennow K, Sáez-Valero J. Characterization of Cerebrospinal Fluid BACE1 Species. Mol Neurobiol. 2019 Dec;56(12):8603–16. doi: 10.1007/s12035-019-01677-8. 摘要:S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749